Viatris 3rd-qtr 2024 results beat estimates
US generic drugmaker Viatris (Nasdaq: VTRS) announced robust financial results for the third quarter of 2024, driven by positive momentum against all three pillars of its strategy. The company’s shares shot up 13.5% to $13.18 following the announcement.
Viatris declared total revenues of $3.8 billion, marking 3% growth on a divestiture-adjusted basis. The company achieved $133 million in new product revenues and repaid around $1.9 billion of debt, reinforcing its financial steadiness.
Key financial metrics for Viatris include net earnings of $95 million on a generally accepted accounting principles (GAAP) basis and adjusted earnings before tax, depreciation and amortization (EBITDA) of $1.3 billion, reflecting an increase of 4% on a divestiture-adjusted basis. Adjusted earnings per share (EPS) rose by 6% to $0.75 per share, which beat the Zacks Consensus Estimate of $0.68.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze